MIND RESearch projects



Cannabidiol (CBD) for Anxiety

This project is an FDA-approved clinical trial of a whole plant-derived, high-CBD sublingual tincture for the treatment of anxiety. Subjects are assessed at baseline and weekly for four weeks of treatment. The primary outcome measures of the study are clinical state measures related to anxiety. Additionally, subjects will complete measures related to quality of life, sleep, and activity levels, and cognitive testing.

Please visit https://clinicaltrials.gov/show/NCT02548559 for more information.

Status: currently enrolling participants for the double-blind phase.

Interested in participating? Visit https://rally.partners.org/study/sublingual_cbd


Please note that enrolled participants will be assigned by chance to the CBD group or the placebo group. Participants have a higher chance of being enrolled in the CBD group. The study staff and the participant will not know which group a participant is in.

CBD for Agitation and Anxiety in Alzheimer's-related dementia

In collaboration with Dr. Brent Forester, we are investigating CBD as a potential treatment for anxiety and agitation that often appears in mild to moderate Alzheimer's Disease. Behavioral symptoms of Alzheimer's Disease, such as anxiety and agitation, often contribute to the caregiver stress associated with caring for a loved one with Alzheimer's. At the moment, there are no FDA-approved treatments for these symptoms, and the current treatment options can have significant negative side effects. This study seeks to discover a safe and effective treatment for anxiety and agitation in those living with Alzheimer's. 

Status: currently enrolling research participants.

Are you or a loved one in participating? Visit https://rally.partners.org/study/mclean_cbd




Investigational New Drug (IND) Approvals

MIND has received FDA approval for a number of INDs:

  • Whole plant-derived high CBD product for anxiety

  • Full spectrum high CBD product for pain

  • Hemp-based, high CBD product for anxiety

  • Whole plant-derived high CBD product for dementia-related anxiety and agitation

Additional IND applications are pending!

Observational study of Medical Cannabis Treatment

This study is a non-invasive investigation of participants who currently hold a certification for medical marijuana for various medical and/or psychological conditions. Subjects are assessed at baseline, prior to beginning their medical marijuana treatment regimen and complete clinical and diagnostic scales/interviews, cognitive testing, measures related to quality of life, sleep, general activities, and where appropriate, a neuroimaging session which assesses brain structure, function, chemistry and white matter integrity. Following their visit, subjects track their use of medical cannabis (MC) products daily (type, mode of use, amount, frequency) using a log system, and are in touch with researchers biweekly. Follow up visits occur at 3 months, 6 months, 12 months, 15 months, 18 months, and 24 months post MC treatment initiation in order to better assess the potential impact of MC on cognitive function and related brain and quality of life measures.

Status: currently enrolling research participants.

Interested in participating? Visit https://rally.partners.org/study/medicalmarijuana

Medical Cannabis for Veterans

The third study examines clinical state and cognition in multiple cohorts of veterans who are using cannabinoids to treat a variety of conditions, including post-traumatic stress disorder (PTSD), insomnia, and pain, or who are naive to cannabis. Veterans are assessed monthly throughout six months of cannabinoid use, and complete measures of clinical state, quality of life, sleep, and pain, and also complete cognitive testing. A subset of veterans will also participate in MRI to examine brain structure, function, and chemistry during six to twelve months of cannabinoid use.

Status: currently enrolling participants.

Interested in participating? Visit https://rally.partners.org/study/mmj_in_vets

Longitudinal Study of Chronic Pain in Older Adults

More than half of older adults report bothersome pain within the past month. Further, opioid use for pain is highest among older adults, yet many complain of inadequate relief, significant side effects and increased risk of opioid-related consequences. Medical cannabis (MC) use is increasingly common among older adults for pain relief; however, the potential benefits, risks, and negative consequences of MC in this population have not been assessed, raising serious public health concerns addressed in this proposal. We recently launched a study to examine the impact of MC use on pain and opioid use in older adults. As with the larger, observational study, all patients are assessed before initiating MC treatment, and complete measures of pain, clinical state, quality of life, sleep, brain structure and function. Use of conventional medications, including opioids, are also closely tracked over the course of treatment.

Status: enrolling participants.

Interested in participating? Visit https://rally.partners.org/study/oa

COVID-19 and Medical Cannabis - Online Survey Study

There is no doubt that the COVID-19 pandemic has affected the lives of millions. Medical cannabis products are used by a diverse group of individuals who commonly use medical cannabis to help cope with a variety of symptoms including those related to chronic pain, mood disorders, anxiety and PTSD, sleep disturbances, etc. However, given the limitation and reduction of many services during the COVID-19 pandemic as well as quarantine recommendations by the Center for Disease Control (CDC), it is likely that medical cannabis use as well as access to medical cannabis products has been disrupted during the pandemic.


We hope to learn more about patterns of medical cannabis use during the COVID-19 pandemic via questionnaires designed to be completed remotely. The survey takes 10-15 minutes to complete and can be done on a laptop, desktop, tablet, or smartphone.

Status: to participate, visit https://redcap.partners.org/redcap/surveys/?s=FERWTKTHXW


Massachusetts Baseline Assessment of Medical Marijuana Patients (BAMMP)

Additional projects for the next phase of MIND are focused on:

Please reload